Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. exitaplasia

ExitAplasia

Reg-X310: new disruptive medicine for faster exit from aplasia afetr agressive chemotherapy of hematologic malignancies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ExitAplasia project word cloud

Explore the words cloud of the ExitAplasia project. It provides you a very rough idea of what is the project "ExitAplasia" about.

difficult    aggressive    speed    days    improvement    treatment    regeneration    faster    25    acquired    feasibility    causes    infection    stay    deaths    actual    death    validation    cells    decrease    costing    severe    million    complete    points    solution    breakthrough    day    risk    health    white    leukaemia    x310    clinical    regstem    opportunity    deficient    turnover    market    stakeholder    with    innovative    dying    disrupt    innovation    shortening    substantially    least    company    blood    hospital    99    21    pasteur    healthcare    start    explore    marking    recovery    red    business    chemotherapy    founded    10    off    immunity    medicine    room    patients    pain    extremely    patient    broaden    found    toxicological    14    fragile    aplasia    commercialisation    changing    2027    reformulate    relation    destruction    70    french    intravenous    paris    situation    sterile    morbidity    tremendous    speeds    ce    length    global    exitaplasia    triggers    game    cancer    spin    reg    world    exit    famous    7    networks    share    jobs    injection    awarded    accelerating    acute    portion    2023   

Project "ExitAplasia" data sheet

The following table provides information about the project.

Coordinator		 REGSTEM 

Organization address
address: 24 RUE DU FAUBOURG SAINT-JACQUES
city: PARIS
postcode: 75014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website https://www.regstem.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REGSTEM FR (PARIS) coordinator 50˙000.00

Map

 Project objective

With more than 3.7 million new cases and 1.9 million deaths each year, cancer represents the second most important cause of death and morbidity in Europe; a significant portion is treated by chemotherapy, which triggers the destruction of red and white blood cells: aplasia. This aggressive treatment results in a severe deficient immunity and an extremely fragile health, which causes patients with leukaemia, for example, to stay 21 days at the hospital in a sterile room costing in average €25,000 per day. In this extremely difficult situation, RegStem has found the high-potential solution: the new Reg-X310 medicine which allows faster red and white blood cells regeneration, accelerating exit from aplasia and shortening hospital length of stay of at least 4 days. It is a tremendous improvement in relation to only existing medicine that speeds out aplasia for only one day. This breakthrough innovation will speed up recovery, decrease the risk of dying from a hospital-acquired infection (~7% less), and decrease healthcare cost for around €100,000/patient. Reg-X310 is a game-changing innovation which will substantially improve the treatment of aplasia and disrupt the market. Reg-X310 is being developed by RegStem, a French awarded innovative company, founded as a spin-off of the world-famous Pasteur Institute in Paris. The ExitAplasia project will allow the company to reformulate the Reg-X310 into an intravenous injection and to start the toxicological and clinical validation as well as the CE marking, necessary for the commercialisation in Europe. To accomplish this goal, RegStem will complete a feasibility study to further analyse users’ pain points and actual trends, as well as broaden European key stakeholder networks and explore new business opportunity. RegStem will lead the European and global acute leukaemia market with 10% market share in 2023 and up to 70% before 2027, which will result in €14 and €99 million turnover, and more than 20 new European jobs

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXITAPLASIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXITAPLASIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More